The Lancet November 17, 2026

Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial

Puliafito BR, Graham CE, Raje NS, Yee AJ, Cirstea DD, Branagan AR, Horick NK, Parker AL, King M, Ogier MG, Leick MB, Gallagher KME, Frigault MJ, Maus MV, et al.

Bottom Line

TriPRIL, a novel dual-targeting CAR T-cell therapy utilizing a trimeric human APRIL ligand to target both BCMA and TACI, demonstrated safety and an 80% response rate in heavily pretreated relapsed or refractory multiple myeloma patients, including those who had previously progressed on BCMA-directed CAR-T.

Key Findings

1. The TriPRIL therapy reduced or eliminated signs of cancer in 80% (12 of 15) of treated patients.
2. Clinical efficacy was observed even in patients who had previously relapsed after receiving standard BCMA-directed CAR T-cell therapies (prior BCMA-directed CAR-T exposure was present in 9 of the 15 enrolled patients).
3. No prohibitive dose-limiting toxicities were reported that would prevent further clinical development, confirming safety for advancing to phase 2 trials.

Study Design

Design
Phase 1 Trial
Open-Label
Sample
15
Patients
Duration
Short-term
Median
Setting
Single center, US
Population Patients with heavily pretreated relapsed or refractory multiple myeloma. The cohort was highly refractory, and 9 of the 15 patients had previously relapsed after receiving a prior BCMA-directed CAR T-cell therapy.
Intervention TriPRIL, an autologous CAR T-cell therapy engineered with a trimeric human APRIL ligand to dually target BCMA and TACI on myeloma cells.
Comparator N/A (Single-arm phase 1 study)
Outcome Safety, including the incidence of dose-limiting toxicities (DLTs) and adverse events.

Study Limitations

• The study was conducted with a very small sample size of only 15 patients.
• The follow-up duration is relatively short, limiting the ability to assess the long-term durability of responses and the potential for late-onset adverse events.
• The single-center, non-randomised phase 1 design precludes any definitive conclusions regarding efficacy compared to current standard-of-care regimens.

Clinical Significance

By utilizing a fully human trimeric ligand to dually target BCMA and TACI, TriPRIL offers a potential mechanism to overcome common causes of CAR-T failure in multiple myeloma, namely single-antigen escape (BCMA loss) and anti-drug antibody formation against non-human CAR components. The robust 80% overall response rate in a population largely refractory to prior BCMA-targeted therapies highlights its clinical promise as a salvage therapy for this difficult-to-treat demographic.

Historical Context

While BCMA-directed CAR T-cell therapies (such as ide-cel and cilta-cel) have transformed the treatment landscape for relapsed/refractory multiple myeloma, patient relapses remain common. These treatment failures are often driven by tumor antigen escape (loss or downregulation of BCMA) or poor CAR T-cell persistence due to immune rejection of the non-human scFv binding domains. TriPRIL was specifically engineered to circumvent these issues by employing a fully human trimeric APRIL ligand that naturally binds both BCMA and a secondary antigen, TACI, thereby reducing immunogenicity and enabling continued tumor recognition even if BCMA expression is lost.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

What is the biological rationale for using a natural human APRIL ligand to target both BCMA and TACI in multiple myeloma, compared to traditional single-antigen CAR T-cells?

Key Response

BCMA is widely expressed on multiple myeloma cells but can be mutated or downregulated after selective pressure from single-antigen BCMA CAR T-cell therapy, leading to resistance. TACI is another receptor found on these malignant plasma cells. Because APRIL (A proliferation-inducing ligand) is the natural biological ligand for both BCMA and TACI, engineering a CAR with a trimeric APRIL ligand allows the T-cell to bind either or both targets simultaneously, theoretically overcoming resistance driven by BCMA antigen escape.

Resident
Resident

A patient with penta-refractory multiple myeloma who relapsed 6 months after receiving ide-cel (a BCMA-directed CAR-T) is being considered for TriPRIL. Why might this patient still respond, and what are the immediate acute toxicities you must monitor for during the admission?

Key Response

The patient may still respond because TriPRIL binds TACI in addition to BCMA; thus, even if the relapse after ide-cel was due to BCMA loss, the CAR-T can still activate via TACI engagement. Clinically, residents must monitor for Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), typically presenting with fever, hypotension, hypoxia, and encephalopathy, managed promptly with tocilizumab and/or corticosteroids.

Fellow
Fellow

Given that TriPRIL utilizes a natural human ligand rather than a murine-derived single-chain variable fragment (scFv), how does this design influence the pharmacological persistence of the CAR T-cells and the risk of immune-mediated rejection?

Key Response

Many first-generation CAR T-cells use murine-derived scFvs, which are highly immunogenic and can induce anti-drug antibodies (ADAs) or anti-CAR cellular immune responses, leading to premature clearance of the CAR T-cells and early relapse. By utilizing a native, fully human APRIL sequence, TriPRIL is expected to be significantly less immunogenic, potentially reducing ADA formation, enhancing the in vivo persistence of the CAR T-cells, and leading to a more durable clinical response.

Attending
Attending

As dual-targeted CAR-T therapies like TriPRIL demonstrate high efficacy in BCMA-exposed relapsed/refractory multiple myeloma, how should this influence our strategic sequencing of T-cell engagers (TCEs) and other novel therapies in heavily pretreated patients?

Key Response

Historically, failure on a BCMA-targeted therapy prompted a pivot to an alternative target like GPRC5D (e.g., talquetamab) or FcRH5. TriPRIL's 80% response rate in BCMA-exposed patients challenges this paradigm, suggesting that BCMA-exposed patients can be effectively salvaged with a dual-targeting natural ligand CAR. Attendings must now weigh whether to re-challenge the BCMA/TACI axis immediately after BCMA failure or reserve it for later, depending on the mechanism of prior failure (e.g., antigen loss vs. T-cell exhaustion).

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

From a bioengineering perspective, how does the use of a trimeric APRIL ligand optimize immunological synapse formation and binding avidity compared to a traditional tandem scFv dual-targeting CAR construct?

Key Response

Tandem scFv CARs (where two distinct scFvs are linked in a single chain) often suffer from steric hindrance, unequal binding affinities, and tonic signaling due to synthetic misfolding. APRIL naturally forms a homotrimer to bind its receptors. By engineered trimerization of the APRIL ligand in the CAR design, the construct mimics physiological receptor-ligand stoichiometry. This spatial geometry improves binding avidity, facilitates a more structured and stable immunological synapse, and reduces the risk of early T-cell exhaustion caused by tonic signaling.

Journal Editor
Journal Editor

Although this phase 1 trial reports an impressive 80% overall response rate, what critical methodological limitations regarding intention-to-treat (ITT) analysis and manufacturing wait times must be scrutinized before validating these efficacy claims?

Key Response

As a seasoned reviewer, one must look for selection bias common in phase 1 autologous CAR-T trials. The reported ORR often only includes patients who successfully received the infusion. The manuscript must be critically appraised for the ITT population—specifically, the dropout rate between apheresis and infusion due to rapid disease progression or manufacturing failures. Without this context, the 80% ORR may artificially inflate the therapy's real-world effectiveness for rapidly progressing RRMM patients.

Guideline Committee
Guideline Committee

If phase 2/3 data validate TriPRIL's efficacy, how should NCCN and ESMO guidelines for multiple myeloma be updated regarding the management of patients who have progressed on prior BCMA-directed therapies?

Key Response

Current guidelines recommend clinical trials or switching to alternative targets (like GPRC5D) for patients relapsing after BCMA-directed CAR-T or bispecifics. If TriPRIL shows durable efficacy with acceptable safety (Level 2A evidence or better), guidelines would need to establish a new pathway for 'BCMA-exposed' patients. The committee would need to formally recommend TriPRIL as a viable salvage option, specifically emphasizing its utility in patients with documented BCMA downregulation, thereby establishing dual-targeted cellular therapy as a distinct class from single-antigen re-treatment.

Clinical Landscape

Noteworthy Related Trials

2021

KarMMa Trial

n = 128 · NEJM

Tested

Idecabtagene vicleucel (ide-cel)

Population

Relapsed or refractory multiple myeloma (at least 3 prior therapies)

Comparator

None (Single-arm)

Endpoint

Overall response rate

Key result: Ide-cel demonstrated an overall response rate of 73%, with 33% of patients achieving a complete response or better.
2021

CARTITUDE-1 Trial

n = 97 · Lancet

Tested

Ciltacabtagene autoleucel (cilta-cel)

Population

Heavily pretreated relapsed or refractory multiple myeloma

Comparator

None (Single-arm)

Endpoint

Overall response rate

Key result: Cilta-cel showed an unprecedented overall response rate of 97%, with 67% achieving a stringent complete response.
2023

KarMMa-3 Trial

n = 386 · NEJM

Tested

Idecabtagene vicleucel (ide-cel)

Population

Relapsed and refractory multiple myeloma (2 to 4 prior regimens)

Comparator

Standard of care (investigator's choice of standard regimens)

Endpoint

Progression-free survival

Key result: Ide-cel significantly prolonged progression-free survival compared to standard regimens (median 13.3 months vs. 4.4 months).

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis
↑